Digital Insomnia Therapy Patents: Who Leads, Trends 2026
Digital Insomnia Therapy Patents: Filing Trends and Leading Claimants
358 of 1,080 records sit with the top five assignees (33.1%) — concentration real but not dominant, leaving room for new entrants to stake out claims. Filings rose from 47 in 2017 to a peak of 171 in 2022, then eased toward 150 in 2024 — an 88% increase over the 2021-to-2024 span. 2025 and 2026 counts are still incomplete because of publication lag and should not be read as a decline.
- 1ABBOTT LAB INC137
- 2ALEXANDER SHULGIN RES INST INC70
- 3COMPASS PATHFINDER LTD57
- 4TRANSCEND THERAPEUTICS INC54
- 5UNIV OF VIRGINIA PATENT FOUND40
See the full digital insomnia therapy analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about digital insomnia therapy patents
How concentrated is the digital insomnia therapy patent field?
It is moderately concentrated but not dominated by a single player. The top five assignees together hold 358 of 1,080 records in scope, or 33.1%, while the top ten reach 42.6%. That leaves well over half of all records spread across a long tail of smaller filers, which means the field is still open to new entrants rather than locked up by a handful of incumbents.
Is patent filing in digital insomnia therapy still growing?
Yes, through the last complete filing year. Filings rose from 80 in 2021 to 150 in 2024, an 88% increase, with a single-year peak of 171 in 2022. Counts for 2025 and 2026 look lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity, so those recent years should not be read as a slowdown.
Are these patents mostly about software or about drugs?
Mostly pharmacological and diagnostic. A61K medicinal preparations appear on 48.4% of the 1,080 records and A61P therapeutic-activity claims on 38.1%, while G06F digital-processing claims appear on only 6.9% and G16H healthcare informatics on 16.1%. A record can carry more than one class, so these figures overlap, but the pattern is consistent: most claims in this search are built around a compound or a diagnostic measurement, not a software mechanism.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Digital Insomnia Therapy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.